Advanced search
Publication Cover
Clinical Toxicology Volume 47, 2009 - Issue 8
Submit an article Journal homepage
100
Views
6
CrossRef citations to date
0
Altmetric
Articles

A retrospective review of California poison control system data of sibutramine exposures

Alicia Bethany Minns Department of Emergency Medicine, Division of Medical Toxicology, University of California, San Diego, California, USACorrespondence[email protected]
,
Shirley Ebrahimi School of Pharmacy, University of San Francisco, San Francisco, California, USA
,
Lena Te School of Pharmacy, University of San Francisco, San Francisco, California, USA
,
Binh Ly Department of Emergency Medicine, Division of Medical Toxicology, University of California, San Diego, California, USA
,
Richard F. Clark Department of Emergency Medicine, Division of Medical Toxicology, University of California, San Diego, California, USA
&
F. Lee Cantrell Department of Clinical Pharmacy, University of California, San Diego, California, USA
Pages 814-817 | Received 27 May 2009, Accepted 24 Jul 2009, Published online: 07 Sep 2009

References

  • Meridia(R) [package insert]. North Chicago, IL: Abbott; 2007.
  • Lee J, Teoh T, Lee T. Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. J Psychosom Res 2008; 64:107–109.
  • Esposito P, Rampino T, Gregorini M. Severe symptomatic hyponatremia during sibutramine therapy: a case report. Am J Kidney Dis 2008; 52:137–139.
  • Perrio MJ, Wilton LV, Shakir SAW. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity 2007; 15:2712–2722.
  • Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2007; 9:378–387.
  • Bronstein AC, Spyker DA, Cantilena LR, Green J, Rumack BH. Heard SE. 2006 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS). Clin Toxicol 2007; 48:815–917.
  • Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003; 26(14):1027–1048.
  • Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure; a metaanalysis of controlled trials. Obes Res 2003; 11(9):1116–1123.
  • McMahon FG, Weinstein SP, Rowe E, Ernst KR, ohnson F, Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16:5–11.
  • Maggioni AP, Caterson I, Coutinho W, Finer N, Gaal LV, Sharma AM, Torp-Pedersen C, Bacher P, Shepherd G, Sun R, James P. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial J Cardiovasc Pharmacol 2008; 52(5):393–402.
  • Daniels SR, Long B, Styne D. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics 2007; 120(1):e147–e157.
  • Binkley K, Knowles SR. Sibutramine and panic attacks. Am J Psychiatry 2002; 159(10):1793–1794.
  • Dogangun B, Bolat N, Rustamov I, Kayaalp L. Sibutramine-induced psychotic episode in an adolescent. J Psychosom Res 2008; 65:505–506.
  • Taflinsji T, Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry 2000; 157(12):2057–2058.
  • Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005; 162(5):954–962.
  • Hoffman R. Understanding the limitations of retrospective analyses of poison center data. Clin Toxicol 2007; 45:943–945.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.